FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
Novartis says trials back Beovu safety in diabetic eye diseaseThere is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to Share XNovartis says trials back Beovu safety in diabetic eye diseasehttps://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/
FDA starts review of Roche’s eye disease drug, setting up 2022 verdictThe FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, Share XFDA starts review of Roche’s eye disease drug, setting up 2022 verdicthttps://pharmaphorum.com/news/fda-starts-review-of-roches-eye-disease-drug-setting-up-2022-verdict/
Roche eyes October decision by FDA for wet AMD implantThe FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related Share XRoche eyes October decision by FDA for wet AMD implanthttps://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/
UK patient group warns COVID could limit access to Novartis’ new eye drugNICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – Share XUK patient group warns COVID could limit access to Novartis’ new eye drughttps://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
